Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C24H33FO6 |
Molecular Weight | 436.5136 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 9 / 9 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12C[C@@]3([H])[C@]4([H])C[C@H](F)C5=CC(=O)CC[C@]5(C)[C@@]4([H])[C@@H](O)C[C@]3(C)[C@@]1(OC(C)(C)O2)C(=O)CO
InChI
InChIKey=POPFMWWJOGLOIF-XWCQMRHXSA-N
InChI=1S/C24H33FO6/c1-21(2)30-19-9-14-13-8-16(25)15-7-12(27)5-6-22(15,3)20(13)17(28)10-23(14,4)24(19,31-21)18(29)11-26/h7,13-14,16-17,19-20,26,28H,5-6,8-11H2,1-4H3/t13-,14-,16-,17-,19+,20+,22-,23-,24+/m0/s1
Molecular Formula | C24H33FO6 |
Molecular Weight | 436.5136 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 8 / 9 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Flurandrenolide is a potent corticosteroid intended for topical use. Flurandrenolide occurs as white to off-white, fluffy, crystalline powder and is odorless. Flurandrenolide is practically insoluble in water and in the ether. Cordran is primarily effective because of its anti-inflammatory, antipruritic, and vasoconstrictive actions. The mechanism of the anti-inflammatory effect of topical corticosteroids is not completely understood. Corticosteroids with anti-inflammatory activity may stabilize cellular and lysosomal membranes. There is also the suggestion that the effect on the membranes of lysosomes prevents the release of proteolytic enzymes and, thus, plays a part in reducing inflammation. Flurandrenolide is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2034 Sources: https://www.ncbi.nlm.nih.gov/pubmed/567487 |
8.74 null [pKd] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | CORDRAN SP Approved UseCordran® (flurandrenolide, USP) is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Launch Date1965 |
PubMed
Title | Date | PubMed |
---|---|---|
Corticosteroid-induced cutaneous atrophy and telangiectasia. Experimental production associated with weight loss in rats. | 1976 Aug |
|
Flesh-colored, rubbery nodules in a young girl. | 2010 May-Jun |
|
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. | 2011 Jul 14 |
|
A high-content biosensor-based screen identifies cell-permeable activators and inhibitors of EGFR function: implications in drug discovery. | 2012 Aug |
Patents
Sample Use Guides
For moist lesions, a small quantity of the cream should be rubbed gently into the affected areas 2 or 3 times a day. For dry, scaly lesions, the ointment is applied as a thin film to affected areas 2 or 3 times daily. Therapy should be discontinued when control is achieved. If no improvement is seen within 2 weeks, reassessment of the diagnosis may be necessary.
Route of Administration:
Topical
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/567487
Cultured rat hepatoma (HTC) cells were grown in the absence of added steroid. Cytosol was incubated with [3H]dexamethasone (3 nM final concentration) with or without competing Flurandrenolide (14-18 h at 00C) and specific binding was measured by the charcoal assay.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 16:15:23 GMT 2023
by
admin
on
Sat Dec 16 16:15:23 GMT 2023
|
Record UNII |
8EUL29XUQT
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QD07AC07
Created by
admin on Sat Dec 16 16:15:23 GMT 2023 , Edited by admin on Sat Dec 16 16:15:23 GMT 2023
|
||
|
WHO-ATC |
D07CC03
Created by
admin on Sat Dec 16 16:15:23 GMT 2023 , Edited by admin on Sat Dec 16 16:15:23 GMT 2023
|
||
|
WHO-VATC |
QD07CC03
Created by
admin on Sat Dec 16 16:15:23 GMT 2023 , Edited by admin on Sat Dec 16 16:15:23 GMT 2023
|
||
|
WHO-ATC |
D07AC07
Created by
admin on Sat Dec 16 16:15:23 GMT 2023 , Edited by admin on Sat Dec 16 16:15:23 GMT 2023
|
||
|
NDF-RT |
N0000175450
Created by
admin on Sat Dec 16 16:15:23 GMT 2023 , Edited by admin on Sat Dec 16 16:15:23 GMT 2023
|
||
|
NDF-RT |
N0000175576
Created by
admin on Sat Dec 16 16:15:23 GMT 2023 , Edited by admin on Sat Dec 16 16:15:23 GMT 2023
|
||
|
NCI_THESAURUS |
C521
Created by
admin on Sat Dec 16 16:15:23 GMT 2023 , Edited by admin on Sat Dec 16 16:15:23 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
CHEMBL1201012
Created by
admin on Sat Dec 16 16:15:23 GMT 2023 , Edited by admin on Sat Dec 16 16:15:23 GMT 2023
|
PRIMARY | |||
|
D005478
Created by
admin on Sat Dec 16 16:15:23 GMT 2023 , Edited by admin on Sat Dec 16 16:15:23 GMT 2023
|
PRIMARY | |||
|
1524-88-5
Created by
admin on Sat Dec 16 16:15:23 GMT 2023 , Edited by admin on Sat Dec 16 16:15:23 GMT 2023
|
PRIMARY | |||
|
1123
Created by
admin on Sat Dec 16 16:15:23 GMT 2023 , Edited by admin on Sat Dec 16 16:15:23 GMT 2023
|
PRIMARY | |||
|
216-196-8
Created by
admin on Sat Dec 16 16:15:23 GMT 2023 , Edited by admin on Sat Dec 16 16:15:23 GMT 2023
|
PRIMARY | |||
|
m5497
Created by
admin on Sat Dec 16 16:15:23 GMT 2023 , Edited by admin on Sat Dec 16 16:15:23 GMT 2023
|
PRIMARY | Merck Index | ||
|
3084
Created by
admin on Sat Dec 16 16:15:23 GMT 2023 , Edited by admin on Sat Dec 16 16:15:23 GMT 2023
|
PRIMARY | |||
|
8EUL29XUQT
Created by
admin on Sat Dec 16 16:15:23 GMT 2023 , Edited by admin on Sat Dec 16 16:15:23 GMT 2023
|
PRIMARY | |||
|
4500
Created by
admin on Sat Dec 16 16:15:23 GMT 2023 , Edited by admin on Sat Dec 16 16:15:23 GMT 2023
|
PRIMARY | RxNorm | ||
|
757869
Created by
admin on Sat Dec 16 16:15:23 GMT 2023 , Edited by admin on Sat Dec 16 16:15:23 GMT 2023
|
PRIMARY | |||
|
100000092412
Created by
admin on Sat Dec 16 16:15:23 GMT 2023 , Edited by admin on Sat Dec 16 16:15:23 GMT 2023
|
PRIMARY | |||
|
1217
Created by
admin on Sat Dec 16 16:15:23 GMT 2023 , Edited by admin on Sat Dec 16 16:15:23 GMT 2023
|
PRIMARY | |||
|
15209
Created by
admin on Sat Dec 16 16:15:23 GMT 2023 , Edited by admin on Sat Dec 16 16:15:23 GMT 2023
|
PRIMARY | |||
|
FLUDROXYCORTIDE
Created by
admin on Sat Dec 16 16:15:23 GMT 2023 , Edited by admin on Sat Dec 16 16:15:23 GMT 2023
|
PRIMARY | |||
|
7606
Created by
admin on Sat Dec 16 16:15:23 GMT 2023 , Edited by admin on Sat Dec 16 16:15:23 GMT 2023
|
PRIMARY | |||
|
DB00846
Created by
admin on Sat Dec 16 16:15:23 GMT 2023 , Edited by admin on Sat Dec 16 16:15:23 GMT 2023
|
PRIMARY | |||
|
SUB07685MIG
Created by
admin on Sat Dec 16 16:15:23 GMT 2023 , Edited by admin on Sat Dec 16 16:15:23 GMT 2023
|
PRIMARY | |||
|
DTXSID2047434
Created by
admin on Sat Dec 16 16:15:23 GMT 2023 , Edited by admin on Sat Dec 16 16:15:23 GMT 2023
|
PRIMARY | |||
|
8EUL29XUQT
Created by
admin on Sat Dec 16 16:15:23 GMT 2023 , Edited by admin on Sat Dec 16 16:15:23 GMT 2023
|
PRIMARY | |||
|
Flurandrenolide
Created by
admin on Sat Dec 16 16:15:23 GMT 2023 , Edited by admin on Sat Dec 16 16:15:23 GMT 2023
|
PRIMARY | |||
|
C47537
Created by
admin on Sat Dec 16 16:15:23 GMT 2023 , Edited by admin on Sat Dec 16 16:15:23 GMT 2023
|
PRIMARY | |||
|
1284000
Created by
admin on Sat Dec 16 16:15:23 GMT 2023 , Edited by admin on Sat Dec 16 16:15:23 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> AGONIST |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |